VJDT
Based on 4 publication(s) in Google Scholar
VJDT is a TREM1 inhibitor that can effectively block TREM1 signaling. VJDT inhibits tumor cell proliferation and migration and induces cell cycle arrest. VJDT has immunomodulatory and antitumor activities, and can be used for the research of tumors such as melanoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.68%
- CAS No.: 2765319-65-9
- Formule: C23H17N3O3
- Masse moléculaire:383.40
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) VJDT
More
Activité biologique
|
IL-6 |
TREM-1 |
VJDT (10-50 μM) induces cell cycle arrest in HepG2 cells and inhibits cell proliferation and migration in B16F10 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
VJDT (20 mg/kg; intraperitoneal injection; every other day; day 8 to 20) in Trem1+/+ mice, when used in combination with anti-PD-1 antibody, exerts a potent antitumor effect[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice treated patient-derived melanoma xenograft TM0094[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection, every other day from day 30 to day 48
-
Result:Significantly suppressed PDX tumor growth.
Downregulated key oncogenic pathways (PI3K-Akt, focal adhesion, IL-18 signaling).
Reduced expression of TREM1 and its target genes (NFKB1, CCL20, IL6, CXCL8).
-
Animal Model:C57BL/6J mice treated B16F10 cells[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection, every other day from day 8 to day 20
-
Result:Completely inhibited tumor growth.
Significantly reduced MDSC frequency, expanded activated CD8+ T cells, and increased IFN-γ-producing CD8+ T cells compared to monotherapies.
Chemical Information
-
CAS No. 2765319-65-9
-
Appearance Solid
-
Masse moléculaire 383.40
-
Formule C23H17N3O3
-
Color White to off-white
-
SMILES
O=C(N1CC2=CC=CC=C2)[C@@H]3C=C(C#N)[C@H]1C(C(N4C5=CC=CC=C5)=O)C3C4=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Liver Int
TREM1+ Neutrophils Determine Immunosuppressive Microenvironment and Immunotherapy Response in Hepatocellular Carcinoma. [Abstract]2026 Jul;46(7):e70726. PMID: 42244441 -
Autoimmunity
Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis. [Abstract]2026 Dec 31;59(1):2620252. PMID: 41588655 -
Cell Biochem Biophys
Pharmacological Inhibition or Silencing of TREM1 Restrains HCC Cell Metastasis by Inactivating TLR/PI3K/AKT Signaling. [Abstract]2024 Sep;82(3):2673-2685. PMID: 38954352 -
bioRxiv
Age-associated modulation of TREM1/2- expressing macrophages promotes melanoma progression and metastasis. [Abstract]2024 Nov 21:2024.11.20.624563. PMID: 39605514
Solvant et solubilité
DMSO : 100 mg/mL (260.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (13.04 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6082 mL | 13.0412 mL | 26.0824 mL | 65.2061 mL |
| 5 mM | 0.5216 mL | 2.6082 mL | 5.2165 mL | 13.0412 mL | |
| 10 mM | 0.2608 mL | 1.3041 mL | 2.6082 mL | 6.5206 mL | |
| 15 mM | 0.1739 mL | 0.8694 mL | 1.7388 mL | 4.3471 mL | |
| 20 mM | 0.1304 mL | 0.6521 mL | 1.3041 mL | 3.2603 mL | |
| 25 mM | 0.1043 mL | 0.5216 mL | 1.0433 mL | 2.6082 mL | |
| 30 mM | 0.0869 mL | 0.4347 mL | 0.8694 mL | 2.1735 mL | |
| 40 mM | 0.0652 mL | 0.3260 mL | 0.6521 mL | 1.6302 mL | |
| 50 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL | 1.3041 mL | |
| 60 mM | 0.0435 mL | 0.2174 mL | 0.4347 mL | 1.0868 mL | |
| 80 mM | 0.0326 mL | 0.1630 mL | 0.3260 mL | 0.8151 mL | |
| 100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.6521 mL |